根据最新的研究动态(Nature 2020 Apr 30. doi: 10.1038/s41586-020-2286-9.),有69种化合物(包括29种FDA批准的药物、12种临床试验药物和28种临床前化合物)有希望用于新冠肺炎的治疗。进一步研究这些潜在靶向药物相关蛋白靶点,会极大的加速新冠治疗药物的开发。
分类 | 靶点 | 病毒相关蛋白 | 化合物名称 | 药物现状 | 参考文献 (PMID或DOI) | ABclonal相关研究工具 |
---|---|---|---|---|---|---|
病毒入侵 | ACE2 | Captopril | Approved (Hypertension) | 9187274 | A4612 | |
Lisinopril | Approved (Hypertension) | 12540854 | ||||
Captopril | Approved (Hypertension) | 9187274 | ||||
Lisinopril | Approved (Hypertension) | 12540854 | ||||
TMPRSS2 | Camostat | Approved (Pancreatitis) | 22496216 | A9126 | ||
Nafamostat | Approved (Anticoagulant) | 10.1128/AAC.01043-16 | ||||
病毒复制 | Cyclophilin | Compound 2 | Pre-clinical | 30074795 | A5097, A4861, RK01236 | |
PI4K-IIIβ | Compound 10 | Pre-clinical | 26885694 | A16416 | ||
核酸合成 | IMPDH2 | Nsp14 | Mycophenolic acid | Approved (Organ rejection) | 5799033 | A9208 |
Ribavirin | Approved (Viral infection) | 22555152 | ||||
Sanglifehrin A | Pre-clinical | 28076787 | ||||
Merimepodib | Clinical Trial | 10878288 | ||||
DCTPP1 | Orf9b | ZINC1775962367 | Pre-clinical | 26771665 | ||
ZINC4326719 | 28145708 | |||||
ZINC4511851 | 28655422 | |||||
转录调节 | BRD2/4 | E | ABBV-744 | Clinical Trial | 31969702 | A12677 |
dBET6 | Pre-clinical | 29764999 | ||||
MZ1 | Pre-clinical | 26035625 | ||||
CPI-0610 | Clinical Trial | 26815195 | ||||
JQ1 | Pre-clinical | 24391744 | ||||
RVX-208 | Clinical Trial | 24391744 | ||||
HDAC2 | Nsp5 | Apicidin | Pre-clinical | 17868033 | A19626 | |
Valproic Acid | Approved (CNS diseases, Cancer) | 11742974; 12840003; 21874153 | ||||
DNMT1 | Orf8 | Azacitidine | Approved | 15899874 | A19679 | |
出核运输 | XPO1 | Nsp4/9/Orf6 | Selinexor | Approved | 30115935 | A19625 |
RAE1 | A6713 | |||||
翻译调节 | eEF1A | Ternatin 4 | Pre-clinical | 26651998 | A11545 | |
eIF4E | 4E2RCat | Pre-clinical | 21507972 | A2162 | ||
eIF4G | A7552, A19990 | |||||
EIF4E2/H | Nsp2 | Zotatifin | Clinical Trial | 10.1158/1538-7445.AM2019-2698 | A4305 | |
LARP1 | N | Rapamycin | Approved (Organ rejection) | 15896331 | A4543 | |
Sapanisertib | Clinical Trial | 21651476 | ||||
MNK1 | Tomivosertib | Clinical Trial | 29526098; 30643286 | |||
MNK2 | ||||||
线粒体核糖体 | MRPs | Chloramphenicol | Approved (Bacterial infection) | '23148581 | A4945, A4527, A5897, A5979, A13197 | |
Tigecycline | 28700943 | |||||
Linezolid | 16127068 | |||||
蛋白加工 | ER α-Glucosidase | IHVR-19029 | Clinical Trial | 29253498; 28197304 | A12725, A19876 | |
GLA | Nsp14 | Migalastat | Approved (Fabry disease) | 10866822 | A5119 | |
FKBP7/10 | Orf8 | Rapamycin, FK-506 | Approved (Organ rejection) | 15896331; 9806833 | A19870 | |
PLOD1/2 | Orf8 | Minoxidil | Approved (Hair loss) | 30481795 | ||
Sec61 | PS3061 | Pre-clinical | 30550790 | A15788 | ||
细胞器酸化 | ATP6AP1 | Nsp6 | Bafilomycin A1 | Pre-clinical | 9572882 | A1209 |
ATP6V1A | M | A14706 | ||||
蛋白降解 | CUL2 | Orf10 | Pevonedistat | Clinical Trial | 19360080 | A5076 |
受体 | SIGMAR1 | Nsp6 | Chloroquine | Approved (Malaria) | 30042674 | A5479 |
SIGMAR1 | Nsp6 | E-52862 | Clinical Trial | 22784008 | ||
SIGMAR1 | Nsp6 | PD-144418 | Pre-clinical | 9144641 | ||
SIGMAR1 | Nsp6 | RS-PPCC | Pre-clinical | 17328523 | ||
SIGMAR1 | Nsp6 | PB28 | Pre-clinical | 16891467 | ||
TMEM97 | Orf9c | Pre-clinical | 16891467 | |||
SIGMAR1 | Nsp6 | Haloperidol | Approved (CNS diseases) | 7925616 | A5479 | |
TMEM97 | Orf9c | Approved (CNS diseases) | 7925616 | |||
F2RL1 | Orf9c | AC-55541 | Pre-clinical | 18720984 | A5103 | |
F2RL1 | Orf9c | AZ8838 | Pre-clinical | 28445455 | ||
F2RL1 | Orf9c | GB110 | Pre-clinical | 20873792 | ||
F2RL1 | Orf9c | AZ3451 | Pre-clinical | 28445455 | ||
转运蛋白 | SLC6A15 | Nsp6 | Loratadine | Approved | 25318072 | |
SLC1A3 | M | UCPH-101 | Pre-clinical | 19161278 | A9712 | |
ABCC1 | Orf9c | Daunorubicin | Approved (Cancer) | 9647783 | A3027, A11153 | |
ABCC1 | Orf9c | S-verapamil | Approved (Hypertension) | 17646169 | ||
细胞分裂 | NEK9 | Nsp9 | Dabrafenib | Approved (Cancer) | 29112787 | A17806 |
CEP250 | Nsp13 | WDB002 | Clinical Trial | US Patent US20170097-359A1 | ||
VCP | Orf10 | CB5083 | Clinical Trial | 26565666 | A1402 | |
VCP | Orf10 | DBeQ | Pre-clinical | 21383145 | ||
细胞骨架 | MARK2/3 | Orf9b | Midostaurin | Approved (Cancer) | 18183025 | A6512 |
MARK2/3 | Orf9b | Ruxolitinib | Approved (Myelofibrosis) | 22037378 | ||
多功能激酶 | CSNK2A2 | N | Silmitasertib | Approved (Cancer) | 21159648; 21174434 | A1616, A13481 |
TMCB | Pre-clinical | 22115617 | ||||
PRKACA | Nsp13 | H-89 | Pre-clinical | 2156866 | A0798, AP0557 | |
免疫与炎症 | RIPK1 | Nsp12 | Ponatinib | Approved (Cancer) | 25801024 | A19580 |
TBK1 | Orf9b Nsp13 | ZINC95559591 | Pre-clinical | 23099093 | A3458, AP1026 | |
PTGES2 | Nsp7 | Indomethacin | Approved (Inflammation, Pain) | 5284360 | A7137, A13440 | |
氧化应激 | LOX | Orf8 | CCT 365623 | Pre-clinical | 31070916 | A11504 |
能量代谢 | NDUFs | Nsp7, Orf9c | Metformin | Approved (Diabetes) | 24843020 | A4602, A8691, A8013, A12858 |
儿茶酚胺代谢 | COMT | Nsp7 | Entacapone | Approved (Parkinson's disease) | 1407012; 9681662 | A4435, A18085 |